Dr. Larry W. Tsai has been Vice President of Clinical Development of Tetraphase Pharmaceuticals since 2015. In this role he establishes clinical development plans and oversees the clinical development of drug candidates from first-in-man through late-stage clinical trials. He joined Tetraphase in 2014 as senior medical director. Prior to Tetraphase, he worked at Aeris Therapeutics where he served most recently as vice president of research and development. Dr. Tsai is also a practicing physician at Brigham and Women’s Hospital in the Medical and Surgical Intensive Care Units, Lung Transplant Service, and an instructor in medicine at Harvard Medical School. He received his medical degree from Harvard Medical School. He then completed a residency in internal medicine at Brigham and Women’s Hospital, followed by fellowships in pulmonary and critical care at University of California, San Francisco School of Medicine and BWH. He is board certified in critical care medicine, internal medicine and pulmonary disease. He has authored over 20 peer-reviewed publications and has received funding from the National Institutes of Health.
Dr. Tsai will be speaking at World Anti-Microbial Resistance Congress USA 2016 about ‘Complexities in clinical trials for anti-bacterial drug development: from patient enrollment to the robustness of data‘. This session will focus on what clinical trials for antibacterial drug development look like right now, how to balance ethical considerations with the need to enroll patients in real-time, and the main challenges faced in trial design and data outputs. To hear from Dr. Larry Tsai and other industry experts, attend World Anti-Microbial Resistance Congress USA 2016, held September 8-9 in Washington, DC.